ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
WEB11 hours ago · The findings were presented in a pair of Sanofi-sponsored late-breaking presentations at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, which was ...
Multiple Sclerosis News Today | Symptoms, Diagnosis, Treatments
WEB6 days ago · Get the latest multiple sclerosis news, patient views, and caregiver perspectives from one of the largest MS communities online.
Cleveland Clinic Expert Shares Updates to Global Diagnostic …
WEB1 day ago · September 23, 2024/ News Updates. Cleveland Clinic Expert Shares Updates to Global Diagnostic Criteria for Multiple Sclerosis Announced at 40th Congress of the European Committee for Treatment and Research of Multiple Sclerosis. This is the first meaningful revision to the standard criteria since 2017 …
FDA approves OCREVUS ZUNOVO subcutaneous injection for …
WEB19 hours ago · Roche has announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC ...
Novel Agent First to Slow Disability in nrSPMS - Medscape
WEB3 days ago · September 20, 2024. 0. 0. COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis ...
Key biomarkers identified for predicting disability progression in ...
WEB4 days ago · A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS). The breakthrough research has the potential to transform ...
'Major moment in MS research' as new Octopus trial starts - BBC
WEBApr 4, 2023 · The Octopus trial - so-called because it is a multi-arm, multi-stage trial - is being run by Prof Jeremy Chataway, from the National Hospital for Neurology and Neurosurgery UCLH in London,...
A Cure for Multiple Sclerosis? Scientists Say Within Our Lifetime
WEBJun 12, 2024 · A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are keeping millions with MS healthier for longer – …
CAR-T therapy for multiple sclerosis enters US trials for ... - Nature
WEBFeb 22, 2024 · The first US trials of engineered cells to treat multiple sclerosis have started recruiting volunteers, raising hopes for a new therapeutic option for this devastating neurodegenerative disease...
FDA Approves First Biosimilar to Treat Multiple Sclerosis
WEBThe U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of...